ReviewClinics in liver disease2018
The Genetics of Pediatric Nonalcoholic Fatty Liver Disease.
Review in Clinics in liver disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2021Guideline
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Childhood: From Disease Heterogeneity to Personalized Care.Journal of personalized medicine · 2026Review
- Lifespan approaches for the prevention and management of steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Ferritin and Liver Steatosis in Children: Interactions Between Metabolic Clustering andInternational journal of molecular sciences · 2026Article
- Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025.Obesity pillars · 2025Review
- Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study.Frontiers in endocrinology · 2025Article
- Efficacy of non-pharmacological treatments in pediatric MASLD: a review of the literature.Frontiers in nutrition · 2025Review
- Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease.World journal of gastroenterology · 2024Article
- Breaking boundaries: Unraveling metabolic dysfunction-associated steatotic liver disease in children of India and Canada.Canadian liver journal · 2024Article
- The Impact and Burden of Dietary Sugars on the Liver.Hepatology communications · 2023Review
- Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: An Obesity Medical Association (OMA) Clinical Practice Statement 2022.Obesity pillars · 2022Article
- Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity.Children (Basel, Switzerland) · 2022Review
- Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.World journal of clinical pediatrics · 2022Review
- Shear wave elastography reveals a high prevalence of liver fibrosis in overweight or obese Hispanic youth.Journal of ultrasonography · 2020Article
- Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.Alimentary pharmacology & therapeutics · 2020Review
- Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study.The Journal of pediatrics · 2020Article
- New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History.Pediatric gastroenterology, hepatology & nutrition · 2019Review
- Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children.Clinical and experimental hepatology · 2019Review
- Hepatic Steatosis-a complex interaction of germs, genes and grub.Pediatric research · 2018Article
- Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease.The Journal of clinical investigation · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in children. Severe fibrosis and cirrhosis are potential consequences of pediatric NAFLD and can occur within a few years of diagnosis. Observations suggest that genetics may be a strong modifying factor in the presentation, severity, and natural history of the disease. There is increasing interest in determining at-risk populations based on genetics in the hope of finding genotypes that correlate to NAFLD phenotype. Ultimately, the hope is to be able to tailor therapeutics to genetic predispositions and decrease disease morbidity in children with NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.